Cargando…
Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
AIM: Several pathophysiological processes are involved in Parkinson’s disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer’s Disease, in a PD cohort. METHODS: Longitudinal cerebrospinal fluid (CSF) samples from PPMI (252 PD, 115 healthy...
Autores principales: | Bartl, Michael, Dakna, Mohammed, Galasko, Douglas, Hutten, Samantha J., Foroud, Tatiana, Quan, Marian, Marek, Kenneth, Siderowf, Andrew, Franz, Jonas, Trenkwalder, Claudia, Mollenhauer, Brit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496858/ https://www.ncbi.nlm.nih.gov/pubmed/34618817 http://dx.doi.org/10.1371/journal.pone.0257372 |
Ejemplares similares
-
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020) -
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020) -
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
por: Kremer, Thomas, et al.
Publicado: (2021) -
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023) -
Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)